ArticleJACC. Advances2026
Perioperative Metabolomic Profiling in Neonatal Cardiac Surgery Identifies a High-Risk Phenotype for Adverse Outcomes.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNeonatal cardiac surgery is associated with high morbidity and mortality. Perioperative metabolic stress may result in distinct metabolic phenotypes associated with adverse clinical outcomes.
objectivesThe purpose of this study was to identify perioperative metabolomic phenotypes associated with adverse clinical outcomes in neonates undergoing cardiac surgery with cardiopulmonary bypass (CPB).
methodsPlasma samples were collected from 230 neonates at 3 institutions at preoperative, post-CPB, and 24-hour time points. Targeted metabolomics was performed via mass spectrometry. Feature selection used the Boruta algorithm, and unsupervised hierarchical clustering (Euclidean distance, Ward's linkage) identified phenotypes. The primary endpoint was a composite of morbidity, including death, extracorporeal membrane oxygenation, cardiac arrest, renal replacement therapy, hepatic injury, elevated lactate, and low cardiac output syndrome.
resultsFifty-one of 76 metabolites passed quality control. Unsupervised clustering identified 3 metabolomic groups with composite outcome rates of 40%, 6.1%, and 58%. For clinical interpretation, these corresponded to intermediate-, low-, and high-risk phenotypes, respectively. The high-risk phenotype was characterized by elevated 24-hour tyrosine, alanine, proline, and methionine, metabolites linked to amino acid catabolism and inflammation. The low-risk phenotype demonstrated higher post-CPB cystine and greater pre/post ratios of galactitol and acetylcarnitine, consistent with preserved redox balance and fatty acid oxidation. Multiple comparison adjustments confirmed associations between these metabolic pathways and clinical outcomes.
conclusionsMetabolomic profiling identified phenotypes associated with risk for adverse outcomes after neonatal cardiac surgery. Amino acid catabolism and inflammatory pathways were linked to morbidity, supporting further evaluation of metabolomic biomarkers for perioperative risk stratification and targeted therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.